+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.

Age: 5Years - 11YearsAll GendersPhase 3
147 locations
R

Actively Recruiting

Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.

Age: 12Years - 17YearsAll GendersPhase 3
155 locations
R

Actively Recruiting

This research focuses on participants who have completed or exited previous clinical studies involving benralizumab Fasenra and are still judged by their doctors to benefit from continued treatment. The study aims to provide continuous access to benralizumab while monitoring its long-term safety and tolerability in conditions such as asthma, eosinophilic granulomatosis with polyangiitis EGPA, and hypereosinophilic syndrome HES. It is an open-label, international, non-randomized study designed to support ongoing treatment beyond initial trials. Participants will receive benralizumab through subcutaneous injections at the same frequency as in their prior parent study. This roll-over study allows those who benefit clinically and lack access to commercial benralizumab to continue treatment under medical supervision. The study is planned to run from July 2026 through December 2029, providing ongoing treatment and monitoring. Throughout the study, participants will attend visits at the investigator site for treatment administration and safety assessments. Researchers will monitor and assess serious and non-serious adverse events from baseline until eight weeks after the last benralizumab dose. The study tracks the long-term safety and tolerability of benralizumab, ensuring participants continue to receive care and monitoring during the treatment period.

Age: 6Years +All GendersPhase 3
47 locations